Why Tutor Perini Stock Trounced the Market on Tuesday | The Motley Fool
Tutor Perini(TPC+7. 75%)has been tapped for inclusion on an index run by a high-profile financial information and analysis company, and investors were there for it on Tuesday. Following the news, they eagerly. . .
Tutor Perini(TPC+7. 75%)has been tapped for inclusion on an index run by a high-profile financial information and analysis company, and investors were there for it on Tuesday. Following the news, they eagerly snapped up shares of the construction company, leaving it with a nearly 8% gain that trading session. Graduation dayJust after market close on Monday,S&P Global's S&P Dow Jones Indices announced modifications to itsS&P MidCap 400andS&P SmallCap 600indexes. Image source: Getty Images. The one that affected Tutor Perini was the looming departure of a fellowconstruction stock,Taylor Morrison Home, from the S&P MidCap 400. Taylor Morrison is being acquired by the once Warren Buffett-ledBerkshire Hathawayand will no longer be an independent company. Taylor Morrison's place in that index will be taken by current S&P SmallCap 600 constituent Krystal Biotech(KRYS0. 07%). In turn, Tutor Perini will supplant Krystal Biotech in that lineup. These changes will take effect prior to market open this Friday, July 24. Today's Change(0. 04%) $0. 03Current Price$72. 47Indexes and effectsWhat we're witnessing is mostly the vaunted "index effect," in other words, the market's usual knee-jerk reaction to a stock either joining an index or "graduating" to one comprised of titles with higher market caps. In either case, the affected stock instantly becomes a target of index funds obligated to stuff their portfolios with index constituents. I should stress that this tends to have little, if any, effect on a company's fundamentals (although it's excellent for some free publicity). Given that, I'd maybe wait for Tutor Perini stock to cool from this news if I were interested in buying it. Eric Volkmanhas no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Berkshire Hathaway, Krystal Biotech, and S&P Global. The Motley Fool has adisclosure policy.